异动解读 | ADMA Biologics股价盘中大跌17.72%,财报符合预期难挡投资者担忧

异动解读
Aug 07

生物制药公司ADMA Biologics Inc(ADMA)今日盘中股价大幅下挫,跌幅高达17.72%,引发市场广泛关注。这一大幅下跌发生在公司发布第二季度财报后,尽管财报整体符合市场预期,但仍未能阻止股价的暴跌。

根据公司最新发布的财报,ADMA Biologics第二季度调整后每股收益为14美分,与分析师预期一致,同时高于去年同期的13美分。公司营收同比增长13.8%,达到1.2198亿美元,但略低于分析师预期的1.2267亿美元。尽管业绩总体表现不俗,但投资者似乎对公司的未来增长前景产生了担忧。

分析人士指出,导致股价大跌的原因可能包括:首先,过去三个月分析师对公司的平均盈利预期下降了约16%,这可能引发了投资者对未来业绩的担忧;其次,考虑到ADMA股价在本季度已上涨4.1%,今年迄今为止更是上涨了10.6%,部分投资者可能选择获利了结,进一步加剧了股价的下跌。此外,尽管华尔街分析师对ADMA的平均评级仍为"买入",但投资者似乎选择了更为谨慎的态度,反映出市场对公司未来发展前景的不确定性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10